venture>> 2014
Companies for tomorrow

venture>> award ceremony: the best business ideas for tomorrow

venture>> TOP 25 ideas

ETH Zürich
Knecht Holding
McKinsey & Company

Swiss Confederation
Commission for Technology and Innovation CTI
Preface

“You jump off a cliff and you assemble an airplane on the way down.”

Reid Hoffman, Co-Founder LinkedIn

Founding a start-up requires courage: Courage to leave the beaten track, courage for decisions under uncertainty, courage to keep going after setbacks. This is why >>venture>> awards its winners not only for their ingenious ideas but also for their courage to transform their ideas into businesses. Of course, >>venture>> also extends a helping hand with personal coaching, workshops, networking opportunities, investor contacts, and jury feedback.

A record number of 239 innovative business ideas were submitted to >>venture>> 2014. We are pleased to present the 25 finalists in this brochure and wish them all the best of success in turning their ideas into flourishing new businesses!

A good idea alone does not yet make a successful entrepreneur. The next step is to develop the idea into a solid business plan. Therefore, we encourage all teams, whether they have been among the winners in the first phase or not, to participate in the business plan phase of the competition – along with any new teams that would like to join the >>venture>> adventure.

We would like to extend our warmest thanks to our coaches and jurors for their commitment and many hours of voluntary work as well as to the >>venture>> advisory board. Without their contribution, >>venture>> 2014 would not have been possible.

Dr. T. Knecht
Knecht Holding

Prof. R. Eichler
ETH Zürich

W. Steinlin
CTI

Dr. M. Winter
McKinsey&Company
## Content

<table>
<thead>
<tr>
<th>Statistics</th>
<th>5</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Winners</strong></td>
<td>8</td>
</tr>
<tr>
<td>Alerion Technologies</td>
<td>8</td>
</tr>
<tr>
<td>Bright Sensors</td>
<td>10</td>
</tr>
<tr>
<td>Caustics</td>
<td>12</td>
</tr>
<tr>
<td>CellSpring</td>
<td>14</td>
</tr>
<tr>
<td>G-Therapeutics</td>
<td>16</td>
</tr>
<tr>
<td>Lunaphore</td>
<td>18</td>
</tr>
<tr>
<td>Play! by Uberchord Engineering</td>
<td>20</td>
</tr>
<tr>
<td>Qloudlab</td>
<td>22</td>
</tr>
<tr>
<td>ReHaptix</td>
<td>24</td>
</tr>
<tr>
<td>Versantis</td>
<td>26</td>
</tr>
<tr>
<td><strong>Finalists</strong></td>
<td>28</td>
</tr>
<tr>
<td><strong>Coaches and jury members</strong></td>
<td>32</td>
</tr>
<tr>
<td><strong>Contact</strong></td>
<td>35</td>
</tr>
</tbody>
</table>
Statistics

»venture« 2014: record number of business idea submissions

Number of business ideas submitted per »venture« edition

<table>
<thead>
<tr>
<th>Year</th>
<th>Number</th>
</tr>
</thead>
<tbody>
<tr>
<td>1998</td>
<td>215</td>
</tr>
<tr>
<td>2000</td>
<td>120</td>
</tr>
<tr>
<td>2002</td>
<td>207</td>
</tr>
<tr>
<td>2004</td>
<td>238</td>
</tr>
<tr>
<td>2006</td>
<td>205</td>
</tr>
<tr>
<td>2008</td>
<td>221</td>
</tr>
<tr>
<td>2010</td>
<td>204</td>
</tr>
<tr>
<td>2012</td>
<td>192</td>
</tr>
<tr>
<td>2014</td>
<td>239</td>
</tr>
</tbody>
</table>

»venture« 2014: key facts

450 Team members of »venture« teams

450 Participants at »venture« events (excl. award ceremony)

109 Coaches are supporting the »venture« teams

94 Jurors evaluated the submitted business ideas

39 Schools with affiliated team leaders

20 Sponsors and partners

10 Events (excl. award ceremony)
Statistics

Industry mix of business ideas: medical sector catching up with IT

Percent of business ideas submitted per industry, 100 percent = 239

<table>
<thead>
<tr>
<th>Industry</th>
<th>Percent</th>
</tr>
</thead>
<tbody>
<tr>
<td>Agriculture / food</td>
<td>41</td>
</tr>
<tr>
<td>Education</td>
<td>16</td>
</tr>
<tr>
<td>Chemicals / materials</td>
<td>10</td>
</tr>
<tr>
<td>Environment / energy</td>
<td>5</td>
</tr>
<tr>
<td>Commerce</td>
<td>7</td>
</tr>
<tr>
<td>Consumer goods</td>
<td>6</td>
</tr>
<tr>
<td>Mechanical engineering</td>
<td>4</td>
</tr>
<tr>
<td>Sport and wellness</td>
<td>6</td>
</tr>
<tr>
<td>Tourism / transport</td>
<td>1</td>
</tr>
</tbody>
</table>

Team leaders: 58 percent with school affiliation

Percent of team leaders, 100 percent = 239

<table>
<thead>
<tr>
<th>Institution</th>
<th>Count</th>
</tr>
</thead>
<tbody>
<tr>
<td>ETHZ</td>
<td>58</td>
</tr>
<tr>
<td>EPFL</td>
<td>22</td>
</tr>
<tr>
<td>FHs</td>
<td>12</td>
</tr>
<tr>
<td>Uni Zurich</td>
<td>11</td>
</tr>
<tr>
<td>Uni St. Gallen</td>
<td>6</td>
</tr>
<tr>
<td>Uni Basel</td>
<td>3</td>
</tr>
<tr>
<td>Uni Lausanne</td>
<td>3</td>
</tr>
<tr>
<td>Uni Bern</td>
<td>3</td>
</tr>
<tr>
<td>Uni Geneva</td>
<td>1</td>
</tr>
<tr>
<td>Uni Svizzera italiana</td>
<td>1</td>
</tr>
<tr>
<td>Others¹</td>
<td>14</td>
</tr>
</tbody>
</table>
Statistics

Team leaders: background
Percent of team leaders, 100 percent = 239

**Professional status**

- Student: 28
- Employee: 42
- Self-employed: 30

**Geographical distribution**

- French-speaking Switzerland: 23
- German-speaking Switzerland: 62
- Other: 15

Winners: strong finish of business ideas within the medical sector

# of business ideas per industry, ten winners only

- Medical technology: 4
- Pharma/biotech: 2
- Energy: 1
- Mech. engineering: 1
- Software: 2

# of teams per school affiliation, ten winners only

- ETHZ: 3
- UZH: 1
- EPFL: 5
- n/a: 1
Winners (in alphabetical order)

Team
Dr. Raymond Oung
Dr. Oier Peñagaricano-Muñoa
Dr. Maciej Stachura
Dr. Jack Elston
Dominique Hunziker

Industry
Mechanical engineering

Place
Zurich

Affiliation
-

Contact
raymond.oung@alumni.ethz.ch
Alerion Technologies

Description
Large ocean tuna fishing vessels find their catch by using underwater sonars and environmental cues as indicators of where a school of fish might potentially be located. Piloted helicopters are then employed to visually verify these potential fishing zones. These missions, however, pose a risk to the pilots and operating vessel; they are also expensive to operate and maintain.

Alerion Technologies has developed a small, unmanned aircraft system (sUAS) that allows for inexpensive and user-friendly real-time remote monitoring. They will provide turn-key, custom sUAS solutions for real-time remote sensing applications. For customers already employing piloted aircraft for remote sensing missions, this mitigates human risk and reduces recurring costs. Immediate customers come from the fishing and forest industry, who operate in regions of the world where UAS regulations are relatively lenient.

Appraisal
One major business advantage of Alerion stems from the fact that the usability of their technology can be applied to numerous business and industry areas. The team consists of experts with complementary profiles combining experience in robotics, aerospace, as well as general electrical and mechanical engineering. Consequently, the team brings along the technological expertise to enter the unmanned aircraft systems market that will have an estimated market volume of USD 80bn in 2025.

Going forward, Alerion can further strengthen their profile by exploring additional market segments beyond the already identified industries and by constantly refining their USP compared to their competition.
In Europe, 260 people die as a result of drug intoxications every day, and another 16,000 are hospitalized with poor prognosis. Besides drugs, endogenous waste products (such as ammonia) can also become life-threatening if they accumulate due to deficient metabolic pathways. Under such circumstances, prompt blood detoxification is crucial to guarantee survival. However, fast, efficacious, and safe toxin-removal procedures are still unavailable.

Versantis is developing a novel universal antidote based on scavenging microvesicles capable of rapidly removing toxic agents from the organism and save patients from acute intoxications. When administered in a peritoneal dialysis setup, these microscavengers (i.e., liposomes, which have been used clinically for more than 25 years) can extract toxins from peripheral tissues and ultimately remove them from the body. Latest results show that the therapy is highly versatile and effective for c. 85% of most common toxic agents.

Winners Versantis

There is a clear need for the toxin-removal procedure developed by Versantis to improve patient safety and outcome. Besides the solid biochemical research, the business idea convinced the jury with a very compelling go-to-market strategy as well as a clear business model. Moreover, Versantis consists of a team of experienced researchers and strong partners.

Going forward, a crucial milestone for Versantis will be the proof of concept in the market of congenital hyperammonemia.

Gaël Farine
Conor Slater

Team

Industry Energy
Place Lausanne
Affiliation EPFL
Contact gael.farine@epfl.ch
Bright Sensors

Description
The natural gas industry is a large and growing market. Natural gas offers many benefits but is subject to high variation in quality. These variations can lower the efficiency of gas appliances during combustion, thus increasing consumption and emissions.

Bright Sensors SA is an EPFL spin-off that develops, manufactures, and sells a natural gas quality sensor to optimize natural gas appliances and biogas production. The sensor can sample a gas in the pipeline and measure its Wobbe Index, a measure of the quality and interchangeability of natural gases. As the sensor is compact and able to operate on low power, it can be easily integrated directly into gas appliances and vehicles. Furthermore, manufacturing can be automated to lower cost. Bright Sensors’ business is based on selling the sensor at large volumes to original equipment manufacturers (OEMs) of the gas industry that integrate it as a feature to their appliances.

Appraisal
Bright Sensors well fits the current trend of monitoring energy efficiency. Integration of the sensor into gas appliances at low manufacturing cost promises substantial revenue potential. Additionally, the business idea is pursued by a very strong team with remarkable industry experience.

Going forward, the team could benefit from bringing in external expertise in sales and marketing within the energy sector in order to identify the most promising market segments and to elaborate the underlying market entry strategies.
The mission of ReHaptix is to develop and market novel technologies to improve assessment and rehabilitation of patients with neurological disorders such as strokes. ReHaptix developed the V-Peg (Virtual Peg Insertion Test), which is an innovative tool for the objective assessment of upper limb sensorimotor functions. It combines a force feedback robotic device, a virtual reality environment, and data analysis software. This device allows clinicians to measure both movement and force during a reaching and grasping task and provides them with precise quantification of the hand disability of their patients, thanks to ReHaptix's unique feature extraction algorithms. The use of the V-Peg will result in robust patient assessment and monitoring. In clinical routine, this will be particularly important for measuring patients' progress and efficacy of therapeutic interventions.

The V-Peg testing approach meets a clear customer need for therapists to get objective measurements of upper limb impairments of their patients in order to evaluate the efficacy of therapeutic interventions and track patients' progress. Furthermore, the patient can visualize the results and see his own progress, which keeps him motivated for training. The team collaborates closely with experienced researchers, neurologists, and therapists, and the business idea has gained credibility through partnerships with hospitals and rehabilitation centers in Switzerland, Belgium, and Canada. Going forward, the team's ability to identify innovative growth opportunities will define long-term profitability, as the size of the current target market appears limited.

Team
Romain Testuz
Prof. Dr. Mark Pauly

Industry
Software

Place
Lausanne

Affiliation
EPFL

Contact
romain.testuz@epfl.ch
Caustics

Description
The interaction of light with physical objects is fundamental to how we perceive the world. 3D objects that are composed of a transparent medium, such as glass, or a reflective surface, such as metals, commonly project bright patterns that are an essential component of this visual perception. These patterns are called caustics.

At the core of Caustics’ innovation is a new algorithm for inverse light simulation that allows users to optimize the shape of an object in such a way as that it will project a target image through the reflection or refraction of light. Beyond applications in glassware and luxury good, such light projections create fascinating new design elements for architecture and furniture design.

Appraisal
Caustics has developed very promising geometry optimization software that could potentially lead to disruptive product innovations in various industries. Its wide areas of application, such as lighting control, interior design, architecture, consumer products, and security, form the basis of its significant business potential.

Going forward, Caustics will need to continue to strive for optimal protection of their technology in order to defend it against potential copycats.
Qloudlab is the inventor and patent holder of the world's first touchscreen-based biosensor. They are developing a cost-effective technology that turns your smartphone touchscreen into a medical device for multiple blood diagnostics testing. Getting started with testing requires no plug-in but just a simple disposable biofilm. Results can be immediately integrated into healthcare data networks, retaining physician involvement in patient care. Thus, Qloudlab is at the convergence of smartphones, healthcare, and cloud solutions.

The development is supported by EPFL and by a major industrial player in cutting-edge touchscreen solutions for consumer, industrial, and automotive products. Qloudlab clearly demonstrated its ability to develop disruptive innovation in the medical technology industry. The fact that no add-on to the mobile phone is required makes the technology beautiful and highly user-friendly. In addition, the team's cooperation with the leading producer of touchscreens as well as their selection of a niche market for testing purposes reveals a very solid knowledge of the business side.

Going forward, the team needs to deepen their understanding of potential regulatory issues that could possibly endanger a successful product launch such as potential requirements for FDA approval of mobile phones in the USA.
CellSpring

Description

For the last half-century, pharmaceutical companies have relied on 2-dimensional cell culture to test potential new medicines. 3D structures, however, mimic human organs and tumors much more closely. Therefore, 3D cell cultures offer a more efficacious and clinically relevant platform to test new drug candidate molecules. The 3D technology currently on the market, however, cannot produce these tissues fast enough, nor with sufficient reliability to meet the needs of lab professionals.

CellSpring has developed a bioadhesion platform, dubbed QuickStick, that enables the formation of 3D, cellular microtissues in a rapid (15 minute) and cell-friendly chemical reaction. These microtissues promise to be the fastest forming, most reliable 3D tissues on the market for drug candidate screening.

Appraisal

There is a clear market need for fast and reliable production of 3D cell cultures as proposed by CellSpring. They strongly differentiate themselves from the competition in respect to time-efficiency and cost levels and a more simplified solution with a highly precise technology.

Going forward, demonstration of equivalence (or virtually equal usability) as compared to conventional 3D cell structures will be a key milestone for continued success of CellSpring.
Learning a musical instrument is tough: Even with the support of a great teacher, it requires dedication, discipline, and time. With new technology have come new ways of learning, such as music learning software. However, the problem with existing music learning software is that they do not work well with polyphonic instruments such as the guitar and that their methodology does not stimulate sustained learning. Play! is a mobile app that teaches you guitar in a completely new way building on the most advanced audio recognition technology. It works also with other polyphonic instruments and provides a new concept to learning a musical instrument. Play!’s algorithm does not only provide feedback on whether the student has played the right chord or not but also identifies and displays the actual chord he or she has played. This unprecedented feature is an enabler that allows Play! to teach you both instrumental technique and harmonics through practical lessons alone. Play! addresses a clear customer need for all musicians in an innovative and unique way. The revenue potential appears solid as an international roll-out is easily conceivable. Going forward, the team should continue to deepen their insight into online marketing and sales in order to define which markets are ideally entered first and what price strategy they wish to adopt. As the technology behind Play! may potentially be copied, an excellent IP protection strategy will be crucial for continued success.
G-Therapeutics

Description  
G-Therapeutics is an EPFL spin-off with the aim of making a fundamentally new treatment paradigm that restored voluntary locomotion in paralyzed animals with a success rate of 100% available for human use. G-Therapeutics is developing an implantable electrochemical spinal neuroprosthesis and a robot-assisted training program to rehabilitate individuals with spinal cord injury.

The entire therapeutic package will include an implantable stimulation system, a pharmacological cocktail for the most severe lesions, and a walk rehabilitation robot. The latter can also be used for walk rehabilitation in wide variety of clinical indications including strokes, multiple sclerosis, Parkinson’s disease, and orthopedics.

Appraisal  
G-Therapeutics rekindles the hope for efficacious treatment of spinal cord injuries. Given clinical success, the potential of the project is great and addresses an urgent need in the market. The team consists of several engineers and medical experts with a strong track record in medical technology.

Going forward, the team needs to continue their quest to demonstrate that the promising research results in animals are also applicable to humans despite potential inter-species differences. Further efforts to translate the team’s research work into a viable business will lay the foundation for commercial success.
The microscopic assessment of biomarker expression patterns on tissues and cells by immunohistochemistry (IHC) is a widely used method in biology and personalized cancer medicine. However, current analysis protocols are time-consuming, labor intensive, and produce variable, inaccurate, and often irreproducible datasets.

Lunaphore is a medtech company that builds next generation tumor analysis and classification platforms. Lunaphore’s IHC assays take just 5 minutes, reduce the number of required reagents by 50%, and remove ambiguities in data by providing 90% higher diagnostic accuracy as validated by clinical studies done with breast cancer patients.

Lunaphore has developed an innovative tumor analysis and classification platform with the potential to be a disruptive alternative to classical immunohistochemistry. Revenue potential is substantial if Lunaphore gains a first-mover advantage in this USD 2.3bn market (2016).

Going forward, two of Lunaphore’s priority areas will be to sharpen their sales and marketing strategy and to gain detailed insights into regulatory affairs.
**Lunaphore**

**Description**

The microscopic assessment of biomarker expression patterns on tissues and cells by immunohistochemistry (IHC) is a widely used method in biology and personalized cancer medicine. However, current analysis protocols are time consuming, labor intensive, and produce variable, inaccurate, and often irreproducible datasets.

Lunaphore is a medtech company that builds next generation tumor analysis and classification platforms. Lunaphore’s IHC assays take just 5 minutes, reduce the number of required reagents by 50%, and remove ambiguities in data by providing 90% higher diagnostic accuracy as validated by clinical studies done with breast cancer patients.

**Appraisal**

Lunaphore has developed an innovative tumor analysis and classification platform with the potential to be a disruptive alternative to classical immunohistochemistry. Revenue potential is substantial if Lunaphore gains a first-mover advantage in this USD 2.3bn market (2016).

Going forward, two of Lunaphore’s priority areas will be to sharpen their sales and marketing strategy and to gain detailed insights into regulatory affairs.
Winners

G-Therapeutics is an EPFL spin-off with the aim of making a fundamentally new treatment paradigm that restored voluntary locomotion in paralyzed animals with a success rate of 100% available for human use. G-Therapeutics is developing an implantable electrochemical spinal neuroprosthesis and a robot-assisted training program to rehabilitate individuals with spinal cord injury. The entire therapeutic package will include an implantable stimulation system, a pharmacological cocktail for the most severe lesions, and a walk rehabilitation robot. The latter can also be used for walk rehabilitation in wide variety of clinical indications including strokes, multiple sclerosis, Parkinson’s disease, and orthopedics.

G-Therapeutics rekindles the hope for efficacious treatment of spinal cord injuries. Given clinical success, the potential of the project is great and addresses an urgent need in the market. The team consists of several engineers and medical experts with a strong track record in medical technology. Going forward, the team needs to continue their quest to demonstrate that the promising research results in animals are also applicable to humans despite potential inter-species differences. Further efforts to translate the team’s research work into a viable business will lay the foundation for commercial success.

Team
Simon Barkow-Oesterreicher
Eckart Burgwedel
Martin Polak
Ilona Maslioukovskagia

Industry
Software

Place
Zurich

Affiliation
University of Zurich

Contact
simon@uberchord.ch
Play! by Uberchord Engineering

Description

Learning a musical instrument is tough: Even with the support of a great teacher, it requires dedication, discipline, and time. With new technology have come new ways of learning, such as music learning software. However, the problem with existing music learning software is that they do not work well with polyphonic instruments such as the guitar and that their methodology does not stimulate sustained learning.

Play! is a mobile app that teaches you guitar in a completely new way building on the most advanced audio recognition technology. It works also with other polyphonic instruments and provides a new concept to learning a musical instrument. Play!’s algorithm does not only provide feedback on whether the student has played the right chord or not but also identifies and displays the actual chord he or she has played. This unprecedented feature is an enabler that allows Play! to teach you both instrumental technique and harmonics through practical lessons alone.

Appraisal

Play! addresses a clear customer need for all musicians in an innovative and unique way. The revenue potential appears solid as an international roll-out is easily conceivable.

Going forward, the team should continue to deepen their insight into online marketing and sales in order to define which markets are ideally entered first and what price strategy they wish to adopt. As the technology behind Play! may potentially be copied, an excellent IP protection strategy will be crucial for continued success.
For the last half-century, pharmaceutical companies have relied on 2-dimensional cell culture to test potential new medicines. 3D structures, however, mimic human organs and tumors much more closely. Therefore, 3D cell cultures offer a more efficacious and clinically relevant platform to test new drug candidate molecules. The 3D technology currently on the market, however, cannot produce these tissues fast enough, nor with sufficient reliability to meet the needs of lab professionals.

CellSpring has developed a bioadhesion platform, dubbed QuickStick, that enables the formation of 3D, cellular microtissues in a rapid (15 minute) and cell-friendly chemical reaction. These microtissues promise to be the fastest forming, most reliable 3D tissues on the market for drug candidate screening.

There is a clear market need for fast and reliable production of 3D cell cultures as proposed by CellSpring. They strongly differentiate themselves from the competition in respect to time-efficiency and cost levels and a more simplified solution with a highly precise technology.

Going forward, demonstration of equivalence (or virtually equal usability) as compared to conventional 3D cell structures will be a key milestone for continued success of CellSpring.
Qloudlab

**Description**

Qloudlab is the inventor and patent holder of the world’s first touchscreen-based biosensor. They are developing a cost-effective technology that turns your smartphone touchscreen into a medical device for multiple blood diagnostics testing. Getting started with testing requires no plug-in but just a simple disposable biofilm. Results can be immediately integrated into healthcare data networks, retaining physician involvement in patient care. Thus, Qloudlab is at the convergence of smartphones, healthcare, and cloud solutions.

The development is supported by EPFL and by a major industrial player in cutting-edge touchscreen solutions for consumer, industrial, and automotive products.

**Appraisal**

Qloudlab clearly demonstrated its ability to develop disruptive innovation in the medical technology industry. The fact that no add-on to the mobile phone is required makes the technology beautiful and highly user-friendly. In addition, the team’s cooperation with the leading producer of touchscreens as well their selection of a niche market for testing purposes reveals a very solid knowledge of the business side.

Going forward, the team needs to deepen their understanding of potential regulatory issues that could possibly endanger a successful product launch such as potential requirements for FDA approval of mobile phones in the USA.
The interaction of light with physical objects is fundamental to how we perceive the world. 3D objects that are composed of a transparent medium, such as glass, or a reflective surface, such as metals, commonly project bright patterns that are an essential component of this visual perception. These patterns are called caustics.

At the core of Caustics' innovation is a new algorithm for inverse light simulation that allows users to optimize the shape of an object in such a way as that it will project a target image through the reflection or refraction of light. Beyond applications in glassware and luxury goods, such light projections create fascinating new design elements for architecture and furniture design.

Caustics has developed very promising geometry optimization software that could potentially lead to disruptive product innovations in various industries. Its wide areas of application, such as lighting control, interior design, architecture, consumer products, and security, form the basis of its significant business potential.

Going forward, Caustics will need to continue to strive for optimal protection of their technology in order to defend it against potential copycats.
ReHaptix

Description

The mission of ReHaptix is to develop and market novel technologies to improve assessment and rehabilitation of patients with neurological disorders such as strokes. ReHaptix developed the V-Peg (Virtual Peg Insertion Test), which is an innovative tool for the objective assessment of upper limb sensorimotor functions. It combines a force feedback robotic device, a virtual reality environment, and data analysis software. This device allows clinicians to measure both movement and force during a reaching and grasping task and provides them with precise quantification of the hand disability of their patients, thanks to ReHaptix’s unique feature extraction algorithms. The use of the V-Peg will result in robust patient assessment and monitoring. In clinical routine, this will be particularly important for measuring patients’ progress and efficacy of therapeutic interventions.

Appraisal

The V-Peg testing approach meets a clear customer need for therapists to get objective measurements of upper limb impairments of their patients in order to evaluate the efficacy of therapeutic interventions and track patients’ progress. Furthermore, the patient can visualize the results and see his own progress, which keeps him motivated for training. The team collaborates closely with experienced researchers, neurologists, and therapists, and the business idea has gained credibility through partnerships with hospitals and rehabilitation centers in Switzerland, Belgium, and Canada. Going forward, the team’s ability to identify innovative growth opportunities will define long-term profitability, as the size of the current target market appears limited.
The natural gas industry is a large and growing market. Natural gas offers many benefits but is subject to high variation in quality. These variations can lower the efficiency of gas appliances during combustion, thus increasing consumption and emissions.

Bright Sensors SA is an EPFL spin-off that develops, manufactures, and sells a natural gas quality sensor to optimize natural gas appliances and biogas production. The sensor can sample a gas in the pipeline and measure its Wobbe Index, a measure of the quality and interchangeability of natural gases. As the sensor is compact and able to operate on low power, it can be easily integrated directly into gas appliances and vehicles. Furthermore, manufacturing can be automated to lower cost. Bright Sensors' business is based on selling the sensor at large volumes to original equipment manufacturers (OEMs) of the gas industry that integrate it as a feature to their appliances.

Bright Sensors well fits the current trend of monitoring energy efficiency. Integration of the sensor into gas appliances at low manufacturing cost promises substantial revenue potential. Additionally, the business idea is pursued by a very strong team with remarkable industry experience.

Going forward, the team could benefit from bringing in external expertise in sales and marketing within the energy sector in order to identify the most promising market segments and to elaborate the underlying market entry strategies.
Versantis

Description

In Europe, 260 people die as a result of drug intoxications every day, and another 16’000 are hospitalized with poor prognosis. Besides drugs, endogenous waste products (such as ammonia) can also become life-threatening if they accumulate due to deficient metabolic pathways. Under such circumstances, prompt blood detoxification is crucial to guarantee survival. However, fast, efficacious, and safe toxin-removal procedures are still unavailable.

Versantis is developing a novel universal antidote based on scavenging microvesicles capable of rapidly removing toxic agents from the organism and save patients from acute intoxications. When administered in a peritoneal dialysis setup, these microscavengers (i.e. liposomes, which have been used clinically for more than 25 years) can extract toxins from peripheral tissues and ultimately remove them from the body. Latest results show that the therapy is highly versatile and effective for c. 85% of most common toxic agents.

Appraisal

There is a clear need for the toxin-removal procedure developed by Versantis to improve patient safety and outcome. Besides the solid biochemical research, the business idea convinced the jury with a very compelling go-to-market strategy as well as a clear business model. Moreover, Versantis consists of a team of experienced researchers and strong partners.

Going forward, a crucial milestone for Versantis will be the proof of concept in the market of congenital hyperammonemia.
Finalists (in alphabetical order)

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Coteries</td>
<td>The future of the digital album: community-driven mobile applications to distribute music and engage with fans. Fans access the full universe of the musician &amp; get an exclusive and authentic feed of content (songs, videos, live streaming, pictures, etc.) coming directly from the source, the artist.</td>
</tr>
<tr>
<td>DNAwatch</td>
<td>A covert marking solution to address luxury watch counterfeit. Invisible nano-structures are integrated to the sapphire watch glass. The marking is made visible under UV light. DNAwatch is simple to use, extremely hard to copy, and can be adopted by all luxury watch brands as all use sapphire glasses.</td>
</tr>
<tr>
<td>ESKIMO</td>
<td>ESKIMO skis make ski tours feasible and enjoyable for all types of users. The skis have mountable engines, which will allow users to save 50% of their time to reach their destination. The ski engine can be de-/mounted with one single screw in few seconds.</td>
</tr>
<tr>
<td>EveryCook</td>
<td>Provides people who do not have enough time to cook or do not know how to cook with a healthier and cheaper alternative to convenience food. The core product is an intelligent, connected cooking device that takes in raw produce and independently processes them to a finished meal.</td>
</tr>
<tr>
<td>Fotokite</td>
<td>Fotokite is a tethered flying camera that may be used by anyone, without any training, immediately, and in virtually any environment. It allows for a new class of both entertainment and professional aerial products. The technology was developed at ETH Zurich and is patent-pending.</td>
</tr>
</tbody>
</table>
## Finalists

<table>
<thead>
<tr>
<th>Company</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Geiger Plus</strong></td>
<td>Geiger counters are simple and low cost, but are hundreds of times less sensitive to radiation than commercial detectors based on photomultiplier tubes. Geiger Plus aims to use emerging photodiode technology to achieve the sensitivity of commercial radiation monitors at Geiger counter prices.</td>
</tr>
<tr>
<td><strong>LockStyler</strong></td>
<td>A revolutionary, patented professional hair colouring system, which allows hairdressers and end-users to apply highlights in a much more simple, clean, and quick way than any offered by any existing solution on the market.</td>
</tr>
<tr>
<td><strong>mindCast</strong></td>
<td>Our vision at mindCast is to bring brain-computer interfaces to everyone and enable people to use their thoughts and feelings to express themselves in exciting new ways. The FUSE project focuses mainly on EEG.</td>
</tr>
<tr>
<td><strong>FUSE</strong></td>
<td></td>
</tr>
<tr>
<td><strong>Nanolive</strong></td>
<td>Nanolive has developed a disruptive proprietary technology, which allows for the very first time to explore a living cell in 3D without damaging it.</td>
</tr>
<tr>
<td><strong>NINU</strong></td>
<td>NINU is the first digital pregnancy companion that offers advice to expectant mothers through an app-hardware-service. NINU offers health tracking of sleep, fitness, stress, and nutrition through wearable sensors. These quantified data allow for better insights for pregnant women and doctors.</td>
</tr>
</tbody>
</table>
Finalists

**PARTwear**
PARTwear is a wireless sensor network for sports applications. It provides the athlete with objective realtime data about his key performance indicators. Excellent accuracy, intuitive usage, and full freedom of movement in real sports situations make PARTwear the perfect fit for sports enthusiasts.

**SamanTree Technologies**
A digital microscopy company with the mission to enable in-vivo histology for tumor resection guidance and early-stage tumor diagnosis.

**Social Commerce and Service Network**
A Social Commerce and Service Network platform, providing small- and medium-sized businesses with an e-service and e-commerce solution integrated with business management back-end software to expand customer marketing reach to consumer products or services, using mobile technology.

**Visible Impact**
Visible Impact integrates project management, communication, and fundraising tools into a single modern IT solution. Visible Impact aims at strongly increasing the efficiency, transparency, and accountability of non-profit organizations and social enterprises.

**Wikirating**
The Wikirating WebApp is a highly scalable platform independent application, which uses the crowd intelligence approach to quickly and effectively evaluate the rating of a company and its products/services. Participating users get a reward to rate companies and their products/services.
Advisory board members

Juhani Anttila
Pascal Kiener
Calvin Grieder
Hariolf Kottmann
Barend Fruithof
Dieter Bambauer
Alexander Zschokke

Christoph Loos
Reinhard Ambros
Markus Neuhaus
Severin Schwan
Urs Rüegsegger
Lukas Braunschweiler
Gilbert Achermann

Klaus Stahlmann
Urs Schäppi
Thierry Léger
Lukas Gähwiler
Matthias Reinhart

Media partner:
McKinsey&Company

www.venture.ch
Coaches and jurors (A-G)

Many thanks to all our coaches and jurors for their time and expertise!

| Ambros Barbara | Claesson Ulf |
| Baumann Brigitte | Cometta Silvano |
| Baumgartner Peter | Crochat Olivier |
| Beciler Barbara | Dahm Felix |
| Belsey Mark | Day Stefan |
| Biedermann Theo | Decker Markus |
| Biggart Helen | Derungs Bruno |
| Binz Kaspar | Dobenecker Gabriele |
| Bjønness Søren | Dubrulle François |
| Blarer Stefan | Dudek Peter |
| Bluth Thomas | Dürr Josef A. |
| Bogdan Boris | Ebnöther Yves |
| Boichat Romain | Fantini Nicola |
| Boyer Irene | Felber Josef |
| Brunner Hans | Feuz Hans Rudolf |
| Brunner Peter O. | Fischer Peter |
| Bührer Adrian | Florez Milagros |
| Burckhardt Peter | Florin Claude |
| Burckhardt Peter E. | Freuler Niklaus K. |
| Bürki Christian | Fülscher Jan |
| Caro Adriel | Gandar Marc |
| Chapero Valentin | Garcia Pedraza Marcos |
| Christen Gert | Gassert Hannes |
| Christen Jakob Mariana | Glauser Markus |
Coaches and jurors (G-M)

Greif Holger
Güttinger Jörg
Gygax Ruedi
Hacklin Aino
Hamilton Rhea
Hardtmuth Alexander
Hartschen Michael
Hasler Philipp
Hatz Jann J.
Hegarty Aoife
Heil Guntram
Helm-Romaneschi Marina
Hilb Michael
Hofer Markus
Hohl Heinz
Hölling Matthias
Hostettler Bernhard
Hotz Peter Georg
Huber Peter
Hutter, Francois
Isenegger Urs
Iwankowska Malgosia
Kalt Adrian
Kaltofen-Ehmann Arnd
Keiser Olivier
Kirschner Lutz

Kiseljak Rudolf
Knecht Stephan
Knight Christopher
Korosec Wolfgang
Kraak Marjan
Krüsi Monika
Kuhlen Francis
Lang Markus
Langensteinklaus
Lingg Hansruedi
Looser Ulrich Jakob
Looser Walter
Mabillard Sébastien
Macina Sergio J.
Margadant Reto
Mariéthoz Jérôme
Martin-Garcia Jesus
Massor Jean-Luc
Matthews Donat
Matuszek Markus
Mayer Felix
McShane Alec
Meister Max
Meyer Jörg
Meyns Silke
Moning Elisabeth
You jump off a cliff and you assemble an airplane on the way down.

Reid Hoffman, Co-Founder LinkedIn

Founding a start-up requires courage: Courage to leave the beaten track, courage for decisions under uncertainty, courage to keep going after setbacks. This is why >>venture<< awards its winners not only for their ingenious ideas but also for their courage to transform their ideas into businesses. Of course, >>venture<< also extends a helping hand with personal coaching, workshops, networking opportunities, investor contacts, and jury feedback.

A record number of 239 innovative business ideas were submitted to >>venture<< 2014. We are pleased to present the 25 finalists in this brochure and wish them all the best of success in turning their ideas into flourishing new businesses!

A good idea alone does not yet make a successful entrepreneur. The next step is to develop the idea into a solid business plan. Therefore, we encourage all teams, whether they have been among the winners in the first phase or not, to participate in the business plan phase of the competition – along with any new teams that would like to join the >>venture<< adventure.

We would like to extend our warmest thanks to our coaches and jurors for their commitment and many hours of voluntary work as well as to the >>venture<< advisory board. Without their contribution, >>venture<< 2014 would not have been possible.

Coaches and jurors (M-W)

Moser Markus
Müller Jürg
Münchbach Martin
Munton Richard
Nagel Christian
Niederberger Martin
Niedermann Claus
Nobile Massimo
Otto Marc
Paiva Pedro
Piatti Marco
Plaksen Evgeny
Plötz Peter A.
Plüss Andreas
Rausch Klaus
Ries Gerhard
Rinella Eugenio
Rohr Norman
Romaneschi Alberto
Romero Maria Carolina
Ruchti Christoph
Ruef Francois
Salameh Constantino
Samanta Fredrik
Schaepman Ellert
Scharf Oliver

Schmid Henri A.
Schubiger Franz
Schwarz Gabriele
Sellam Zaki
Sethi Anil
Spierenburg Pieter
Steinberger Philipp
Steiner Roger
Stephan Véronique
Strasser Ralph
Suter Christian
Tripet Jean-Phillippe
Turner Colin
Ullman Fredrik
Uzuev Alexey
Valentine Graham
Vonesch Peter J.
Vunder Fontana Kadri
Wagner Karen
Watts Michael
Wensauer Dominik
Wibmer Jeannette
Williams Virginia
Wlodarczak Dominik
Wood Bryan
Contact

»venture» office
Rütistrasse 14
8952 Schlieren

Phone: +41 (0)58 332 23 30
Fax: +41 (0)44 876 91 03

Email: office@venture.ch

www.venture.ch

Imprint

»venture» 2014 is a joint initiative of ETH Zurich, Knecht Holding AG, the federal innovation promotion agency CTI, and McKinsey & Company Switzerland.

Team photos were provided by participating teams; description of business ideas and appraisals were prepared by the »venture» office based on jury feedback.

Editing and design: Reto Zollinger (cover; info@retozollinger.ch) and »venture» office (content pages).

Reproduction of the contents of this booklet is authorized, provided the source is acknowledged.

Zurich, January 2014